270 related articles for article (PubMed ID: 18160562)
1. Use of recombinant activated factor VII to arrest uncontrolled bleeding: a case series.
Alsayegh F; Fakeir A; Alhumood S; Abdumalek K; Matar H; Samaul I; Nampoory N; Kabalawi H; Mousa SA
Clin Appl Thromb Hemost; 2009; 15(2):225-32. PubMed ID: 18160562
[TBL] [Abstract][Full Text] [Related]
2. Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
Tomita E; Takase H; Tajima K; Suematsu Y
Asian Cardiovasc Thorac Ann; 2017 Feb; 25(2):99-104. PubMed ID: 28114794
[TBL] [Abstract][Full Text] [Related]
3. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
Pychyńska-Pokorska M; Pągowska-Klimek I; Krajewski W; Moll JJ
J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):987-94. PubMed ID: 21835642
[TBL] [Abstract][Full Text] [Related]
4. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.
Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF
Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023
[TBL] [Abstract][Full Text] [Related]
5. Use of recombinant activated factor VII in intractable bleeding during pediatric neurosurgical procedures.
Uhrig L; Blanot S; Baugnon T; Orliaguet G; Carli PA; Meyer PG
Pediatr Crit Care Med; 2007 Nov; 8(6):576-9. PubMed ID: 18062085
[TBL] [Abstract][Full Text] [Related]
6. Use of recombinant activated factor VII (Novoseven) in trauma and surgery: analysis of outcomes reported to an international registry.
Grounds RM; Seebach C; Knothe C; Paluszkiewicz P; Smith TS; Kasal E; Lecumberri R; Urbanec R; Haas T; Wujtewicz M; Rehorkova D; Pelichovska M; Lange M; Uranga M; Bosman R; Rommes JH; Koscielny J
J Intensive Care Med; 2006; 21(1):27-39. PubMed ID: 16698742
[TBL] [Abstract][Full Text] [Related]
7. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage.
Hauser CJ; Boffard K; Dutton R; Bernard GR; Croce MA; Holcomb JB; Leppaniemi A; Parr M; Vincent JL; Tortella BJ; Dimsits J; Bouillon B;
J Trauma; 2010 Sep; 69(3):489-500. PubMed ID: 20838118
[TBL] [Abstract][Full Text] [Related]
8. [Activated recombinant factor VII (Novoseven) in multiple trauma patients: an outcome analysis].
Grinţescu I; Tulbure D; Mirea L
Chirurgia (Bucur); 2006; 101(6):615-24. PubMed ID: 17283837
[TBL] [Abstract][Full Text] [Related]
9. Role of recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery.
Končar IB; Davidović LB; Savić N; Sinđelić RB; Ilić N; Dragas M; Markovic M; Kostic D
J Vasc Surg; 2011 Apr; 53(4):1032-7. PubMed ID: 21215579
[TBL] [Abstract][Full Text] [Related]
10. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery.
Bishop CV; Renwick WE; Hogan C; Haeusler M; Tuckfield A; Tatoulis J
Ann Thorac Surg; 2006 Mar; 81(3):875-9. PubMed ID: 16488687
[TBL] [Abstract][Full Text] [Related]
11. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
12. Hemostatic agents for bleeding: recombinant-activated factor VII and beyond.
Franchini M; Crestani S; Frattini F; Sissa C; Bonfanti C
Semin Thromb Hemost; 2015 Apr; 41(3):342-7. PubMed ID: 24937097
[TBL] [Abstract][Full Text] [Related]
13. Emerging off-label uses for recombinant activated factor VII: grading the evidence.
Enomoto TM; Thorborg P
Crit Care Clin; 2005 Jul; 21(3):611-32. PubMed ID: 15992675
[TBL] [Abstract][Full Text] [Related]
14. Adequacy of hemostatic resuscitation improves therapeutic efficacy of recombinant activated factor VII and reduces reexploration rate for bleeding in postoperative cardiac surgery patients with refractory hemorrhage.
Feih JT; Juul JJ; G Rinka JR; Baumann Kreuziger LM; Pagel PS; Tawil JN
Ann Card Anaesth; 2019; 22(4):388-393. PubMed ID: 31621674
[TBL] [Abstract][Full Text] [Related]
15. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
[TBL] [Abstract][Full Text] [Related]
16. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
17. Recombinant activated Factor VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation.
Fischer D; Schloesser R; Buxmann H; Veldman A
J Pediatr Hematol Oncol; 2008 May; 30(5):337-42. PubMed ID: 18458565
[TBL] [Abstract][Full Text] [Related]
18. Using recombinant activated factor VII, B-Lynch compression, and reversible embolization of the uterine arteries for treatment of severe conservatively intractable postpartum hemorrhage: new method for management of massive hemorrhage in cases of placenta increta.
Mechsner S; Baessler K; Brunne B; Albrecht T; Hopp H; Dudenhausen JW
Fertil Steril; 2008 Nov; 90(5):2012.e1-5. PubMed ID: 18462726
[TBL] [Abstract][Full Text] [Related]
19. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
[TBL] [Abstract][Full Text] [Related]
20. The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage.
Boffard KD; Choong PI; Kluger Y; Riou B; Rizoli SB; Rossaint R; Warren B;
Transfusion; 2009 Dec; 49 Suppl 5():240S-7S. PubMed ID: 19954486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
